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a proton pump inhibitor, lansoprazole, enhances nuclear accumulation of Runx2 and induces osteoblastogenesis
of humanmesenchymal stromal cells. Systemic administration of lansoprazole to a rat femoral fracturemodel in-
creased osteoblastogenesis. Dissection of signaling pathways revealed that lansoprazole activates a noncanonical
bone morphogenic protein (BMP)-transforming growth factor-beta (TGF-β) activated kinase-1 (TAK1)–p38
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lansoprazole enhances polyubiquitination of the TNF receptor-associated factor 6 (TRAF6) and by in vitro
ubiquitination studies that the enhanced polyubiquitination of TRAF6 is attributed to the blocking of a
deubiquitination enzyme, cylindromatosis (CYLD). Structural modeling and site-directed mutagenesis of CYLD
demonstrated that lansoprazole tightly ﬁts in a pocket of CYLD where the C-terminal tail of ubiquitin lies.
Lansoprazole is a potential therapeutic agent for enhancing osteoblastic differentiation.








The major transcription factor runt-related transcription factor 2
(Runx2) plays a pivotal role in regulating chondroblast maturation and
decision of the osteoblastic cell fate of the mesenchymal stem cells
(MSCs) (Marie, 2008). The p38 mitogen-activated protein kinase
(MAPK) and its upstream activator, transforming growth factor-beta
(TGF-β) activated kinase-1 (TAK1), are crucial for the activation and, to
a lesser extent, the expression of Runx2 in osteoblastogenesis
(Greenblatt et al., 2010). In physiological cellular processes, TGF-β–bone
morphogenetic protein (BMP) signaling transmits information through
MAP kinase pathways by leveraging an adaptor molecule, TNF receptor-
associated factor 6 (TRAF6), as well as canonical signaling molecules,
Smads (Xie, 2013). TRAF6, which possesses the ubiquitin E3 ligase activ-
ity, is bound to TGF-β–BMP type I receptors and autopolyubiquitinated by
itself. Unlike Lys48-linked polyubiquitination for proteasome-dependent
protein degradation, TRAF6 catalyzes Lys63-linked polyubiquitination
for intracellular signal transduction (Kulathu and Komander, 2012). The
complex of TAK1–TAK1 binding protein (TAB) speciﬁcally recognizes.
. This is an open access article underTRAF6-conjugated Lys63-linked polyubiquitin chains and utilizes them
as a scaffold for the assembly of TAK1 kinase complexes, which facilitates
TAK1-mediated autophosphorylation of TAK1 itself and subsequent acti-
vation of downstream p38 MAPK (Sorrentino et al., 2008; Yamashita
et al., 2008). Accordingly, Runx2 is upregulated through the TGF-β–BMP
receptor (BMPR)–TRAF6–TAK1–p38MAPK axis. Meanwhile, recent stud-
ies have witnessed emerging roles of the deubiquitination enzymes
(DUBs) targeting to TGF-β–BMP type I receptors or some Smadmolecules
(Trompouki et al., 2003; Herhaus and Sapkota, 2014). One of the DUBs,
cylindromatosis (CYLD), speciﬁcally catalyzes disassembly of Lys63-
linked polyubiquitination and negatively regulates TGF-β–BMP and nu-
clear factor-kappa B (NF-κB) pathways.
The drug repositioning strategy, in which a drug currently used for a
speciﬁc disease is applied to another disease, has gained increasing atten-
tion from both academia and industry in recent years (Abbott, 2002;
Rothstein et al., 2005; Bian et al., 2009; Yamamoto et al., 2013;
Matsushita et al., 2013; Takamatsu et al., 2014). The advantage of this
strategy is that the identiﬁed drugs can be readily applied to clinical prac-
tice, because the optimal doses, adverse effects, and contraindications are
already established. In this study, we identiﬁed by the drug repositioning
strategy that lansoprazole, a proton pump inhibitor (PPI), upregulates
Runx2 and induces osteoblastogenesis. We also proved the effect ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sibilities of clinical application.Wedissected the effect of lansoprazole and
found that lansoprazole induces TRAF6 polyubiquitination, which then
activates the noncanonical TAK1–p38 MAPK pathway and upregulates
Runx2. Furthermore, in silico analysis predicted and site-directed muta-
genesis revealed the binding of lansoprazole to a CYLD pocket and the in-
hibition of its deubiquitination activity by lansoprazole, which leads to
enhanced polyubiquitination of TRAF6.
2. Materials and Methods
2.1. Cell Culture
We purchased mouse pluripotent mesenchymal C3H10T1/2 cells and
human osteoblastic osteosarcoma (HOS) cells from Riken BioResource
Center. We isolated primary bone marrow cells (BMCs) from 6-week-
old male Sprague–Dawley (SD) rats as described previously (Takamine
et al., 2002). We obtained human BMCs during surgery from 3 patients
aged 9 years or younger with idiopathic acetabular dysplasia of the hip
or osteonecrosis of the femoral head after appropriate written informed
consent was given with prior approval by the ethical review committee
of Nagoya University Graduate School of Medicine. We isolated
monocyte-enriched fractions from the collected human BMCs by density
gradient centrifugation with Ficoll-Paque (GE Healthcare) as described
(Kitoh et al., 2004). Mesenchymal progenitors of rat and human were
isolated by their binding ability to culture dishes. To seek for ex vivo appli-
cability of lansoprazole in clinical settings,we also expanded humanmes-
enchymal progenitors in StemPro (Gibco) medium. MSCs and
mesenchymal progenitors were then subjected to differentiation in
osteogenic medium containing 50 μg mL−1 ascorbic acid, 10 mM β-
glycerophosphate, and 10−7 M dexamethasone. Additional information
is provided in the Supplemental Materials and Methods.
2.2. Western Blot Analysis and Immunoprecipitation
HumanMSCs were starved for 1 d in growth medium containing 1%
fetal bovine serum (FBS) before addition of 20 μM lansoprazole. After
15 min of incubation, we added 100 ng mL−1 recombinant BMP-2 for
0, 15, and 30 min. Cells were lysed in RIPA lysis buffer (Santa Cruz Bio-
technology) supplemented with protease and phosphatase inhibitors.
After centrifugation for 15min at 18,000×g, supernatantswere subject-
ed to SDS-PAGE, followed by blotting onto PVDFmembrane.We collect-
ed HOS cells after treatmentwith or without 20 μM lansoprazole for 2 d.
We extracted nuclear and cytosolic fractions using the Nuclear Extrac-
tion kit (Cayman) according to the manufacturer's protocols. At the
same time, we prepared a whole cell lysate by transferring a part of
the cells to RIPA lysis buffer. For immunoprecipitation assay, collected
HOS cells were lysed in passive lysis buffer containing 50 mM HEPES,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM
EGTA, 100 mM NaF, and 10 mM sodium pyrophosphate supplemented
with protease and phosphatase inhibitors, and incubated for 20 min,
followed by centrifugation at 18,000 ×g for 15 min. After a two-fold di-
lution with the dilution buffer containing 50 mMHEPES, 150 mMNaCl,
0.1% Triton X-100, and 1 mM EDTA supplemented with protease and
phosphatase inhibitors, immunoprecipitation was performed by incu-
bation with 2 μg of antibody for overnight, followed by addition of
Dynabeads Protein G to the diluted supernatant. The antibodies used
are shown in the Supplemental Materials and Methods.
2.3. In Cellulo Protein Ubiquitination Assay Using Cultured Cells
HEK293 cells were transiently transfected with Flag-tagged human
TRAF6 cDNA in a CMV-based expression vector, which was a kind gift
of Drs. Jun Ninomiya-Tsuji at North Carolina State University and
Kunihiro Matsumoto at Nagoya University, using FuGENE 6 (Roche).
After 1 d of culture, cells were subjected to complete serum starvationfor 1 d, and then pretreated with or without lansoprazole for 30 min,
followed by stimulation with or without 100 ng mL−1 recombinant
BMP-2 for the indicated time periods. For immunoprecipitation analy-
sis, cells were washed twice, scraped in ice-cold PBS, and centrifuged
at 18,000 ×g for 5 min. Non-covalent protein interactions were dissoci-
ated with 1% SDS and boiling for 5 min. Samples were diluted in PBS
(1:10) containing 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40
supplemented with protease inhibitors, and centrifuged at 18,000 ×g
for 15 min. Immunoprecipitation was performed by incubation with
an anti-Flag M2 antibody (Sigma-Aldrich) overnight, followed by addi-
tion of Dynabeads Protein G (Invitrogen). The resultant immunoprecip-
itates were subjected to SDS-PAGE, followed by immunoblotting with
antibodies against M2 Flag and ubiquitin to visualize TRAF6-associated
polyubiquitin chains.
2.4. In Vitro Protein Ubiquitination Assay in a Test Tube
Human ubiquitin, ubiquitin-activating enzyme (E1), and UbcH5c
(E2) were purchased from Abcam. Ubc13–Uev1a complex (E2) was
purchased from Boston Biochem. Humanwild-type CYLD cDNA (Kazusa
DNA Research Institute) was cloned into pcDNA3.1(+) vector with a
Flag tag at the C-terminal end. An R758A-single-mutant and an R758A
and F766A-double-mutant Flag-tagged CYLD expression vectors were
constructed using QuikChange site-directed mutagenesis kit (Strata-
gene). TRAF6 and CYLD were expressed in HEK293 cells and afﬁnity-
puriﬁed using anti-DYKDDDDK agarose beads (Wako Pure Chemical
Ind.). Polyubiquitin chainswere synthesized at 30 °C for 1 h in a reaction
mixture containing 200 ng E1, 100 ng UbcH5c or Ubc13–Uev1a com-
plex, 1–2 μg TRAF6, and 5 μg ubiquitin in buffer B (50 mM Tris–HCl
pH 7.5, 10 mMMgCl2, 1.5 mMDTT, 5 mMATP) with the indicated con-
centrations of lansoprazole. The reaction was terminated by addition of
SDS sample buffer (Invitrogen), and subjected to immunoblotting anal-
ysis. For deubiquitination reaction, the polyubiquitination chains were
synthesized as above butwithout lansoprazole and the reactionwas ter-
minated by adding 10mMEDTA. The reactionmixturewas subsequent-
ly pretreated with increasing amounts of lansoprazole for 15 min,
followed by incubation with 100–200 nM CYLD in a reaction mixture
containing 24 mM Tris–HCl pH 7.5 and 0.7 mM DTT at 30 °C for 1 h.
2.5. Animals
All animal care and handling conformed to the Regulations on Ani-
mal Experiments in Nagoya University and were approved by the Insti-
tutional Animal Care and Use Committee in Nagoya University. We
purchased male Jcl:SD rats from CLEA Japan and made a rat model of
left femoral fracture. Rats took 7.5 mg kg−1 d−1 of lansoprazole
(Wako Pure Chemical Ind.) in drinking water, which was about 10
times more than the amount used for humans, and administration of
the expected amount of lansoprazole was conﬁrmed by monitoring
water intake twice a week. For radiological analysis, 8-week-old rats
were administered with lansoprazole or vehicle for 4 weeks (n = 6
per group). For histological analysis, ten-week-old rats were adminis-
tered with lansoprazole or vehicle for 4 weeks (n = 8 per group). For
analyzing an early phase of fracture repair, 8-week old rats were admin-
istered with lansoprazole or vehicle for 2 weeks (n= 4 per group). For
analyzing a long-term effect of lansoprazole on intact metaphysis,
unoperated rats were administered with lansoprazole or vehicle for
twelve weeks (n= 4 per group). To label the mineralization front, we
subcutaneously injected calcein (Dojindo, 8 mg per kg body weight)
in 2% sodium hydrogen carbonate twice before being sacriﬁced.
2.6. Rat Model of Fracture Repair
All surgical procedures were conducted under sterile conditions.
Rats were anesthetized by intraperitoneal injection of 30mg kg−1 sodi-
um pentobarbital. A lateral incision on the left hindlimb was made to
Fig. 1. Lansoprazole induces nuclear accumulation of Runx2 and activates its transcriptional activity. (a) Immunoblotting of Runx2 in the nuclear and cytosolic fractions as well as in the
whole cell lysate of HOS cells after adding 20 μM lansoprazole for 2 d. The relative expression levels were densitometrically estimated using an essential splicing factor U2AF35 for the
nuclear fraction and Gapdh for the cytosolic fraction and the whole cell lysate as a control. Lanso., lansoprazole. (b) Runx2-speciﬁc immunoﬂuorescence staining of HOS cells treated
with lansoprazole for 3 d. Scale bar, 50 μm. (c) Activity of Runx2-responsive luciferase reporter vector (6xOSE2-luc) in C3H10T1/2 cells. Cells were exposed to 20 μM of lansoprazole
for 1 d without adding BMP-2. pCMV6-XL5-Runx2, human RUNX2 cDNA clone. (d) Expression levels of endogenous Spp1 mRNA by real-time RT-PCR in C3H10T1/2 cells. Cells were
pretreated with 100 ng mL−1 of recombinant BMP-2 for 3 d, followed by incubation with the indicated concentrations of lansoprazole for 14 d. The relative expression levels were nor-
malized to themean of vehicle. (e) ALP activity of cell lysates of human bonemarrow-derivedmesenchymal cells. Cells were cultured in osteogenicmedium for 19 d and lansoprazolewas
added from days 15 to 19. The relative activity was normalized to the mean of vehicle. (f) ALP staining of human bonemarrow-derived mesenchymal cells, which were treated with the
indicated concentrations of lansoprazole. Cellswere cultured in osteogenicmedium for 24 d and lansoprazolewas added fromdays 18 to 24. Scale bar, 5mm. In (c–e), themean±SD (n=
6) are indicated. *p b 0.0001 by unpaired t-test (c) and by the Jonckheere–Terpstra trend test over the indicated concentration range of lansoprazole (d and e). (d, e, and f) In the course of
our analysis, 5–20 μM lansoprazole exhibits consistent dose–response effects, but data at concentrations less than 5 μMandmore than 20 μMhave not been omitted under the expectation
that these concentrations will be of some help for future references.
2048 K. Mishima et al. / EBioMedicine 2 (2015) 2046–2061expose the shaft of femur. A 3-mm bone defect was created at the mid-
shaft using a thin oscillating saw (NSKDental LLC), and then periosteum
was stripped circumferentially on both sides of osteotomy to prevent
early bone union. Once a 1.2-mm diameter wire (Mizuho Corp.) was
inserted from the cross-section into the proximal femoral canal in a ret-
rogrademanner, the both ends of osteotomy sitewere placed in contact
with each other, and then thewire was reinserted across the osteotomy
site into the distal femoral canal to apply stability. All rats were given
prophylactic administration of sulfamethoxazole (50 mg kg−1 d−1,
Sigma-Aldrich) and trimethoprim (10 mg kg−1 d−1, Sigma-Aldrich),and randomly assigned to receive either lansoprazole or vehicle. At 2
or 4 weeks after fracture, fractured femurs were extracted.
2.7. Radiological Assessment of Fracture Repair
At 1, 2, 3, and 4 weeks after fracture, lateral radiographs of the frac-
tured hindlimb were made using a Multi soft X-ray ﬁlm shooting appa-
ratus (SOFTEX). Fracture union was deﬁned by the formation of
seamless bridging callus on at least one cortex on the lateral radiograph.
After extracting femurs, bridging callus formation on 4 cortices was
Fig. 2. Lansoprazole upregulates the expression of Runx2 and matrix calcium deposition. (a) Expression levels of endogenous Runx2mRNA by real-time RT-PCR in BMP-2-pretreated
C3H10T1/2 cells. Cells were treated with lansoprazole for 2 d. The relative expression levels were normalized to the mean of vehicle. (b) Expression levels of endogenous RUNX2
mRNA by real-time RT-PCR in HOS cells. Cells were treated with lansoprazole for 2 d. The relative expression levels were normalized to the mean of vehicle. (c) Expression levels of en-
dogenous Runx2 protein in BMP-2-pretreated C3H10T1/2 cells. Cells were treated with lansoprazole for 3 d. Densitometric values were normalized to that of Gapdh and also to vehicle.
(d) Expression levels of endogenous Runx2 protein in HOS cells. Cells were treated with lansoprazole for 3 d. Densitometric values were normalized to that of Gapdh and also to vehicle.
(e) Expression levels of endogenous RUNX2mRNA by real-time RT-PCR in human MSCs. The relative expression levels were normalized to the mean of vehicle. Sequential protocol of
lansoprazole administration is indicated at the bottom. Lower arrowheads indicate the time points when we passaged cells. (f) Matrix calcium deposition by Alizarin red staining in
human bone marrow-derived mesenchymal cells that were induced to differentiate immediately after isolation. Cells were cultured in osteogenic medium for 21 d and lansoprazole
was added from days 15 to 21. Scale bars, 5 mm for dishes and 200 μm for magniﬁed images. Note that the temporal protocol of human bone marrow-derived mesenchymal cells in
(f) is different from that of human MSCs in (e), because the time courses of differentiation of these cells are different. (g) Matrix calcium deposition by Alizarin red staining in human
bonemarrow-derived mesenchymal cells that were induced to differentiate after proliferation for 23 d. Cells were proliferated in non-osteogenic medium for 23 d followed by additional
culture in osteogenic medium up to day 44, and lansoprazole was added from days 24 to 44. In (f), cells were differentiated immediately after isolation, whereas in (g), cells were ﬁrst
proliferated for 23 d to increase the number of cells. Scale bars, 5 mm. In (a, b, and e), the relative expression levels were normalized to the mean of vehicle, and the mean ± SD (n=
6) are indicated. *p b 0.01 (a), *p b 0.0001 (b), *p b 0.01 (c, days 0–10), *p b 0.001 (c, days 11–17), and *p b 0.002 (c, days 18–24) by the Jonckheere–Terpstra trend test over the indicated
concentration range of lansoprazole. In (c and d), the densitometric values were normalized to that of Gapdh and also to vehicle.
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Fig. 3.Orally administered lansoprazole accelerates fracture healing in a rat model of femoral fracture. (a) Representative radiographs of vehicle- and lansoprazole-administered rats at 1,
2, 3, and 4weeks after fracture. Formation of seamless bridging callus (black arrowhead) and incomplete formation of uniting callus (white arrow) are shown. The proportion of rats with
the fracture union is indicated in the inset. LAT, lateral view, AP, anteroposterior view. (b) The number of rats showing the indicated number of seamless bridging calluses (left) and com-
plete uniting calluses (right) (n= 6 per group). Bridging callus formation on 4 cortices was evaluated on the anteroposterior and lateral radiographs, and the number of calluses was
counted (0 to 4). Uniting callus formation was deﬁned by the disappearance of fracture line on the anteroposterior and lateral radiographs, and the number of calluses was counted (0
to 2). (c) Representative images of new bone formation within the anchoring callus assessed by double calcein labeling at 4 weeks after fracture. *p b 0.03 by unpaired t-test.
2050 K. Mishima et al. / EBioMedicine 2 (2015) 2046–2061evaluated on the anteroposterior and lateral radiographs, and the num-
ber of seamless bridging calluses in the 4 cortices was counted (0 to 4).
In addition, bridging callus area was measured on ImageJ software.
Uniting (intramedullary) callus formation was determined by the dis-
appearance of fracture line on the anteroposterior and lateral radio-
graphs and its number was counted (0 to 2).2.8. Bone Histological and Morphometrical Analyses
Bone specimens were sequentially dehydrated with 70% ethanol,
90% ethanol, and acetone. The specimenswere then embeddedwithout
decalciﬁcation in methyl methacrylate. We prepared 6-μm sagittal sec-
tions of the whole femur and 30-μm transverse sections at the
Fig. 4. Orally administered lansoprazole accelerated osteoblastic differentiation in a rat model of femoral fracture. (a) Undecalciﬁed bone histology of the fracture sites in vehicle- and
lansoprazole-administered rats (Villanueva Goldner staining) 4 weeks after fracture. Green signals show calciﬁed bones. Red signals show granulation tissues spanning edges of
osteotomy. Note newly formed bone (arrows) in the lansoprazole-treated rat. Scale bar, 1 mm (upper) and 200 μm (lower). (b) Histomorphometric analyses of undecalciﬁed bone his-
tology of the fracture sites showing enhanced bone formation in lansoprazole-treated rat femurs. Themean±SD (n=8) are indicated. *p b 0.02 (BV/TV), *p b 0.04 (Ob.S/BS), and *p b 0.05
(OS/BS) by unpaired t-test. Lanso., lansoprazole. (c) Undecalciﬁed bone histology of the metaphyses of the fracture femur in vehicle- and lansoprazole-administered rats (Villanueva
Goldner stain) 4weeks after fracture. Red signals showosteoid bones. Note increased osteoid formation in the lansoprazole-treated rat. Scale bar, 100 μm. (d)Histomorphometric analyses
of undecalciﬁed bone histology of themetaphyses of the fractured femur. Themean± SD (n=8) are indicated. *p b 0.04 (OV/BV), *p b 0.02 (OS/BS) and *p b 0.05 (N.Oc/BS) by unpaired t-
test. Lanso., lansoprazole; and NS, not signiﬁcant.
2051K. Mishima et al. / EBioMedicine 2 (2015) 2046–2061osteotomy sites with a microtome, and stained them with Villanueva
Goldner stain. Bone parameters of the fracture sites were blindly evalu-
ated by computer-assisted histomorphometry using Osteomeasure
software (OsteoMetrics). For analysis of bone regeneration in the frac-
ture sites, we compared the area of newly formed bone with that of
granulation tissue, and calculated bone volume per granulation tissue
volume (BV/TV) without setting deﬁnite region of interest (ROI) in
the fracture sites.We summed bone histomorphometric values of sagit-
tal and transverse sections to assess osteoblastogenesis in the fracture
sites. In the fractured femurs, after excluding pin track areas in the distal
femur, we deﬁned the ROI in the metaphysis as the areas between
0.7 mm and 3.0 mm proximal to the growth plate in order to excludethe primary trabecular spongiosa. Cartilaginous callus areawasmeasured
using histological sections stained with alcian blue. Total callus area was
deﬁned as the sum of bridging callus area and anchoring callus area,
andwasmeasured by ImageJ software. Histological imageswere obtained
using a BX51 (Olympus) with an UPlanFL N 20× and 0.50 objective lens
(Olympus) ﬁtted with a DXC-390P camera (Sony) and a microscope
M60 (Leica) with a 1.0× objective lens ﬁtted on a camera IC80 (Leica).
2.9. In Cellulo Osteoclast Formation
RAW 264.7 cells (Riken BioResource Center), a mouse macrophage-
like cell line, were seeded onto a 96-well plate at a cell density of
2052 K. Mishima et al. / EBioMedicine 2 (2015) 2046–20612 × 105 cells perwell and cultured for 4 dwith orwithout lansoprazole in
the presence of receptor activator of NF-κB ligand (RANKL)
(100 ng mL−1; Peprotech). Tartrate-resistant acid phosphatase (TRAP)-
positive cells with more than 3 nuclei were counted as osteoclasts.2.10. In Cellulo Bone Resorption Assay
The pit formation assay was performed using a calcium phosphate-
coated plate obtained from PG research (Kodaira, Japan). RAW 264.7
2053K. Mishima et al. / EBioMedicine 2 (2015) 2046–2061cells grown in α-MEM medium were cultured in a 48-well calcium
phosphate-coated plate (5 × 103 cells per well) with or without
lansoprazole in the presence of RANKL (100 ng mL−1) for 7 d. After re-
moving the cells by washing the plate with 5% sodium hydrochloride
solution, digital images of the resorption pits were captured. The pit
area wasmeasured following conversion of the original images to bina-
ry images with NIH ImageJ software.
2.11. Statistical Analysis
All data are presented as the mean and SD. We evaluated dose–
responses using the Jonckheere–Terpstra trend test for the whole
range of drug concentrations. Statistical difference between 2 groups
was determined by the unpaired t-test. We considered a p
value b 0.05 as statistically signiﬁcant.
3. Results
3.1. Lansoprazole Upregulates Runx2
Runx2 is translocated into the nucleus where it binds to the cis-
acting osteoblast-speciﬁc element 2 (OSE2) on promoters of the osteo-
genic genes including Alpl encoding alkaline phosphatase (ALP) and
Spp1 encoding osteopontin (Otto et al., 2003). We screened 1186 FDA-
approved compounds for activating the human RUNX2 P1 promoter in
mouse pluripotent mesenchymal C3H10T1/2 cells and found that
lansoprazole increased the RUNX2 P1 promoter activity in a dose-
dependent manner (Fig. S1a). We found that lansoprazole enhanced
intranuclear accumulation of Runx2 (Figs. 1a, b, S1b, and c), which sub-
sequently stimulated theOSE2 reporter plasmid (Fig. 1c) and upregulat-
ed Spp1mRNAexpression (Fig. 1d) aswell as ALP activity (Fig. 1e and f).
We also conﬁrmed that lansoprazole induced expressions of Runx2
mRNA and Runx2 protein in mouse osteoprogenitor cells (Fig. 2a and
c) and human osteoblastic cells (Fig. 2b and d). In addition, lansoprazole
increased expressions of Runx2mRNA at all stages of osteogenic differ-
entiation in both human MSCs (Fig. 2e) and rat BMCs (Fig. S1d). We
used BMP-2 to differentiate mouse C3H10T1/2 cells into mature osteo-
blasts. In contrast, we used osteogenic medium to differentiate human
and rat primary BMCs, because we hoped to examine the applicability
of lansoprazole in clinical settings. In surgical lengthening of limbs, we
differentiate MSCs in patient's bone marrow aspirates into osteoblast-
like cells ex vivo and inject the differentiated cells into the distraction
gap to promote bone formation (Kitoh et al., 2004). We thus added
lansoprazole to cultured bonemarrow cells thatwere obtained frompe-
diatric patients undergoing acetabular osteotomy after appropriate
written informed consents were given, and found that lansoprazole ac-
celerated the matrix calcium deposition in a dose-dependent manner
(Fig. 2f). We next examined the effect of lansoprazole on expanded
MSCs, and observed more prominent effects (Fig. 2g) rather than
those on the immediately differentiated cells (Fig. 2f). As longer time
exposure to 40 μM lansoprazole decreased the number of cells and sub-
sequently reduced the matrix calcium deposition (Fig. 2g), we used
20 μM lansoprazole as a default concentration in the following studies.Fig. 5. Lansoprazole upregulates the noncanonical BMP–TAK1–p38MAPK pathway. (a) Expressi
out BMP-2 pretreatment. Cells were treated with the indicated concentrations of lansoprazole
C3H10T1/2 cells pretreatedwith 400 ngmL−1 of noggin for 2 d. Cells were treatedwith the indi
kinase inhibitors on lansoprazole-induced increases of RUNX2 P1 promoter activity. C3H10T1/2
2 pretreatment were treated with the indicated kinase inhibitors for 1 h and subsequently trea
lansoprazole, and we decided to use 20 μM in later analyses. The luciferase activities were no
amount of cell lysates. BMPRI kinase inhibitor, dorsomorphin (1 μM); Erk1/2 inhibitor, U0126 (
hibitor, 5Z-7-oxozeaenol (1 μM). *p b 0.0001 by unpaired t-test. (d) Phosphorylation of BMP sig
phosphorylated to total proteins normalized to the ratio without lansoprazole. (e) Effects of TA
MSCs. *p b 0.02 and **p b 0.0003 by unpaired t-test. Human MSCs (LONZA) were cultured in th
oxozeaenol), and 5 μMp38MAPK inhibitor (SB203580) for 14 d. (f) Lansoprazole activates inter
2 d, and immunoprecipitatedwith anti-Runx2 antibody. Immunoprecipitated CBPwas visualize
the Jonckheere–Terpstra trend test (a and b).3.2. Lansoprazole Accelerates Fracture Repair and Osteoblastic
Differentiation in a Rat Fracture Model
To address the clinical relevance of lansoprazole for bone regenera-
tion, we examined the effect of lansoprazole on bone regeneration in a
rat model of femoral fracture (Mills and Simpson, 2012). The rats took
lansoprazole in drinking water for 4 weeks, which was about 10 times
higher than the regular dose used for gastroduodenal ulcer in human.
A human equivalent dose (HED) for rodents is 6 to 13 times higher
than the human dose (Reagan-Shaw et al., 2008), and the HED of 10 is
frequently applied to rodents (Dourson et al., 1996; Foronda et al.,
2007; Bian et al., 2009). No signiﬁcant differences in body weights
were observed between both groups at baseline and during the experi-
mental period (Fig. S2). At 3 weeks after fracture, 5 of the 6 rats (83%)
achieved fracture union in the lansoprazole-treated group, whereas
only 1 of the 6 rats (17%) achieved fracture union in the vehicle-
treated group. At 4 weeks, fracture union was observed in all of the
lansoprazole-treated rats, whereas it was observed in 4 rats (67%) in
the vehicle group (Fig. 3a). The total callus areas, however, were not sig-
niﬁcantly different between the 2 groups at 4 weeks (Fig. S3a). The for-
mation of bridging callus and uniting callus, which succeeds the
formation of anchoring callus (Marino et al., 1979), tended to be better
in the lansoprazole group than the vehicle group (Fig. 3b). Dynamic
analysis of bone formation with calcein double-labeling showed that
lansoprazole enhanced new osteoblastic bone formation in the anchor-
ing callus (Fig. 3c). Histomorphometric analyses at 4 weeks after frac-
ture demonstrated that compared with vehicle-treated rats (n = 8),
lansoprazole-treated rats (n = 8) signiﬁcantly increased the ratios of
bone volume/tissue volume (BV/TV), osteoid surface/bone surface
(OS/BS), and osteoblast surface/bone surface (Ob.S/BS) in the gap of
the fracture site (Figs. 4a, b, S3b and Table S1). Similarly, at the
metaphysis that was penetrated by a wire, lansoprazole signiﬁcantly
enhanced the ratios of osteoid volume/bone volume (OV/BV) and oste-
oid surface/bone surface (OS/BS), while the bone volume/tissue volume
(BV/TV) remained unchanged. In contrast, osteoclast number/bone sur-
face (N.Oc/BS), an osteoclastic parameter, was signiﬁcantly decreased at
the injured metaphysis (Figs. 4c, d, S3b, and Table S2). In addition, at
2 weeks after fracture, when the formation of cartilaginous callus and
its subsequent resorption by osteoclasts take place, systemic adminis-
tration of lansoprazole signiﬁcantly inhibited osteoclastogenesis but
not chondrogenesis at the fracture site (Fig. S4a–c). Taken together,
lansoprazole can facilitate osteoblast differentiation and inhibit osteo-
clast differentiation around the injured site of the bone such as the an-
choring callus and the metaphyses penetrated by a wire.3.3. Lansoprazole Activates the Noncanonical BMP–TAK1–p38 MAPK
Signaling
We next pursued molecular mechanisms of the effects of
lansoprazole. We ﬁrst found that lansoprazole induce expressions of
Runx2 gene even when BMP-2 was not added (Fig. 5a), although the ef-
fect was less prominent compared to that observed with BMP-2-added
C3H10T1/2 cells (Fig. 2a). Native C3H10T1/2 cells have been shown toon levels of endogenous Runx2mRNAby real-time RT-PCR in native C3H10T1/2 cellswith-
for 2 d. (b) Expression levels of endogenous Runx2mRNA by real-time RT-PCR in native
cated concentrations of lansoprazole for 2 d. (c) Effects of BMP signaling-associated protein
cells that stably express pGL4-hRunx2P1-luc2 (C3H10T1/2-hRunx2P1 cells) without BMP-
ted with 20 μM lansoprazole for 1 d. In addition, we expected future clinical application of
rmalized to those without lansoprazole and the kinase inhibitors and also to the protein
20 μM); p38 inhibitor, SB203580 (20 μM); JNK inhibitor, SP600125 (10 μM); and TAK1 in-
naling-associated proteins in humanMSCs. Relative levels indicate densitometric ratios of
K1 and p38 MAPK inhibitors on lansoprazole-induced increases of ALP activity in human
e osteogenic medium with or without 20 μM lansoprazole, 100 nM TAK1 inhibitor (5Z-7-
actions of Runx2 andCBP. HOS cellswere treatedwith orwithout 20 μMof lansoprazole for
d by immunoblotting. In (a–c), themean± SD (n=6) are indicated. NS, not signiﬁcant by
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(Phimphilai et al., 2006). To conﬁrm that lansoprazole required BMPs,
we blocked the binding of BMPs to BMP receptors with noggin, and
found that noggin abrogated the effect of lansoprazole (Fig. 5b). Accord-
ingly, lansoprazole cannot substitute for the activity of BMPs to induce
osteoblastogenesis in C3H10T1/2 cells, but can enhance the effect of
BMPs. We thus scrutinized BMP-signaling pathways leading to Runx2
activation using kinase inhibitors. Inhibitors of p38 MAPK and TAK1
markedly attenuated the effect of lansoprazole, whereas inhibitors of
BMP type I receptor (BMPRI) and Erk1/2 had little or no effects (Fig.
5c). Similarly, lansoprazole increased phosphorylation of p38 MAPK
and TAK1, while phosphorylation of Smad1/5/8 and Erk1/2 remained
unchanged (Fig. 5d). Conversely, inhibitors of p38MAPK and TAK1 sig-
niﬁcantly suppressed lansoprazole-induced ALP activity in humanMSCs
(Fig. 5e).We also conﬁrmed that lansoprazole enhanced the association
of Runx2 with a transcriptional coactivator CREB-binding protein (CBP)
(Fig. 5f). Taken together, lansoprazole speciﬁcally activates the nonca-
nonical BMP–TAK1–p38MAPK signaling pathway by directly potentiat-
ing a molecule downstream of BMPR but upstream of TAK1, and
enhances osteoblastic differentiation. Lansoprazole consequently rein-
forced the ability of Runx2 to recruit a transcriptional activator.
3.4. Lansoprazole Activates TRAF6-anchored Polyubiquitination
Wenext looked for a target molecule that is activated by lansoprazole
and is located downstream of BMPR and upstream of TAK1. An ubiquitin
ligase TRAF6 directly binds to the TGF-β–BMP receptors, and is an imme-
diate downstream effector of the receptors (Landstrom, 2010). TRAF6-
catalyzes TGF-β–BMP-induced Lys63-linked autopolyubiquitination
of TRAF6 itself, which enhances autophosphorylation of TAK1 and
subsequently activates NF-κB (Chen, 2005). Unlike Lys48-linked
polyubiquitination,which is operational in ubiquitin–proteasome-depen-
dent protein degradation, Lys63-linkedpolyubiquitination serves tomod-
ulate a signaling activity of the polyubiquitination-bearing molecule. We
found that lansoprazole increased theNF-κB-responsive luciferase report-
er activity (Fig. 6a). Introduction of a dominant-negative TRAF6 inhibited
the effect of lansoprazole by 60.8 ((1.308–0.512)/1.308) ± 13.9 (0.182/
1.308)% (mean and SD, n= 6) (Fig. 6b). As these experiments pointed
to the notion that TRAF6 is likely to be a direct target of lansoprazole,
we next performed a ubiquitination assay of TRAF6. Upon overexpression
of TRAF6 and BMP-2 induction, lansoprazole enhanced TRAF6-anchored
polyubiquitination in HEK293 cells and primary osteoblasts (Figs. 6c
and S5a). Furthermore, lansoprazole induced TRAF6-anchored
polyubiquitination in a serum-freemediumandwithout BMP-2 induction
(Fig. 6d), which suggested that TRAF6was likely to be a direct targetmol-
ecule activated by lansoprazole. We also found that lansoprazole-
mediated TRAF6-anchored polyubiquitination was indeed linked to
Lys63 by immunoblotting (Fig. S5b and c).
TRAF6 can bind to BMP type II receptor (BMPRII) in the absence of
BMPRI. On the other hand, TRAF6 can bind to BMPRI only when a
BMPRI-II complex is formed by BMPs (Yamashita et al., 2008). As
lansoprazole enhanced polyubiquitination of TRAF6 even in the absence
of BMP ligands, we examined if lansoprazole is able to activate TRAF6
tethered on BMPRII. To this end, we added a TRAF6-inhibitory peptide,
which functions as a TRAF6 decoy by binding to the TRAF6-binding
motif on BMPRI (Poblenz et al., 2007). As expected, we found that the
TRAF6-inhibitory peptide did not compromise lansoprazole-mediated ac-
tivation of RUNX2 P1 promoter activity (Fig. S5d). Lansoprazole is thus
likely to operate onBMPRII-engagedTRAF6 in the absence of BMP ligands.
3.5. Lansoprazole Attenuates Deubiquitination Activity of CYLD In Vitro
To prove that the TRAF6 autopolyubiquitination is indeed a target of
lansoprazole, we examined the effect of lansoprazole by an in vitro
ubiquitination assay (Fig. S6a). Unexpectedly, however, lansoprazole
failed to enhance the synthesis of TRAF6-anchored polyubiquitination(Fig. 7a). As binding of a small compound to a speciﬁc domain of a target
molecule mostly inhibits the target molecule rather than activating it,
we searched for a molecule that antagonizes TRAF6 polyubiquitination.
We found that a deubiquitination enzyme, CYLD, speciﬁcally cleaves
Lys63-linked polyubiquitin chains, and downregulates TRAF6-
mediated signal transduction, which has been characterized in NF-κB
activation (Trompouki et al., 2003). As has been previously reported
(Xia et al., 2009), CYLD was able to cleave unanchored polyubiquitin
chains but not TRAF6-anchored ones in vitro (Fig. S6b). We then exam-
ined the effect of lansoprazole on CYLD using unanchored polyubiquitin
chains, and found that the cleavage was inhibited by pretreatment of
lansoprazole in a dose-dependent manner (Fig. 7b).
3.6. Lansoprazole Stably Fits in a Pocket of CYLD
We next asked if lansoprazole is able to bind to CYLD. An in silico
search for ligand-binding sites of CYLD disclosed a unique pocket
(Fig. 7c). The pocket was located across which the C-terminal tail of
ubiquitin was predicted to lie according to structural alignment of
CYLD to homologous HAUSP-USP7 that was crystallized with ubiquitin.
Optimization of the docking structures predicted that lansoprazole
linked to CYLD by hydrogen bond, σ–п conjugation, and п–п interaction
(Fig. 7d). The docked structure model suggests that lansoprazole sup-
presses deubiquitination activity of CYLD by inhibiting the binding of
the C-terminal tail of ubiquitin to CYLD. The active site of CYLD is pre-
dicted to be located where the C-terminal tail of ubiquitin ends. To
prove that lansoprazole binds to the predicted pocket of CYLD, and in-
hibits its deubiquitination activity, we next employed the Ubc13–
Uev1a complex as an E2 enzyme, which speciﬁcally catalyzes unan-
chored Lys63-linked polyubiquitin chains (Xia et al., 2009). We ﬁrst
conﬁrmed that lansoprazole attenuates wild-type CYLD-mediated
cleavage of the polyubiquitin chains (Fig. 7e). As simulation of serial al-
anine substitutions in the identiﬁed CYLD pocket predicted that R758
and R766 were essential residues for the binding to lansoprazole, we
engineered an R758A-single-mutant CYLD and an R758A and F766A-
double-mutant CYLD. Each mutant CYLD retained a dose-dependent
deubiquitination activity in vitro (Fig. S6c and d), whereas the single
mutant CYLD partly and the double mutant CYLD completely abolished
lansoprazole-mediated suppression of the deubiquitination activities
(Fig. 7f and g). Thus, the mutations exclusively affected responsiveness
of lansoprazole but not the deubiquitination activity of CYLD in the ab-
sence of lansoprazole. These results indicated that speciﬁc binding of
lansoprazole to the CYLD pocket prevents the C-terminal tail from
reaching the active site, which then facilitates TRAF6-mediated
polyubiquitination (Fig. 8).
3.7. Lansoprazole Increases Osteoclast Maturation and Bone Resorption
Activity
To verify whether CYLD is the molecular target of lansoprazole
from other aspects, we examined the effects of lansoprazole on oste-
oclast differentiation and bone-resorbing function using RAW 264.7
cells, in which a critical role of CYLD and TRAF6 has been shown
downstream of receptor activator of NF-κB (RANK) — RANKL signal-
ing (Jin et al., 2008; Tanaka et al., 2003). Lansoprazole signiﬁcantly
increased the proportion of large osteoclasts at a concentration of 1
to 2.5 μM compared to vehicle without affecting the total number
of osteoclasts (Fig. 9A). On the other hand, higher concentrations of
lansoprazole more than 10 μM markedly decreased osteoclasts
formation compared to vehicle probably due to cytotoxicity (Fig.
9a). Bone resorption activity, evaluated by the pit formation assay,
was signiﬁcantly increased by addition of lower concentrations
of lansoprazole less than 1 μM (Fig. 9b). Lansoprazole is thus
capable of enhancing osteoclast maturation and bone resorbing
activity in cellulo.
Fig. 6. Lansoprazole upregulates TRAF6 polyubiquitination. (a) Activity of NF-κB-responsive-element (RE) luciferase reporter vector in C3H10T1/2 cells. Lanso., lansoprazole
(20 μM); TNF-α (1 ng mL−1). *p b 0.0001 by unpaired t-test. (b) Effects of a dominant negative TRAF6 (pDeNy-hTRAF6) on a lansoprazole-induced increase of the RUNX2 P1
promoter activity. A relative luciferase activity was normalized to that of vehicle, and a difference to the vehicle is shown by the mean and SD (n = 6). Lanso., lansoprazole.
(c) Lansoprazole enhanced TRAF6-anchored polyubiquitination with BMP-2 induction in HEK293 cells. (d) Lansoprazole induced TRAF6-anchored polyubiquitination without
BMP-2 induction in HEK293 cells.
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Osteomalacia-like Condition In Vivo
To explore the in vivo effect of lansoprazole-mediated enhance-
ment of osteoclast maturation and sustained activation of Runx2,
we examined both acute and chronic effects of lansoprazole on phys-
iological cancellous bone remodeling in rats. To this end, rats were
fed with the same amount of lansoprazole as that in the fracturemodel for 4 and 12 weeks, and unfractured femurs were harvested.
No signiﬁcant differences in body weights were observed between
both groups at baseline and during the experimental period
(Fig. S7). Systemic administration of lansoprazole for 4 weeks signif-
icantly elevated osteoclastic parameters, whereas static and dynamic
osteoblastic parameters remained unchanged (Figs. 10a and S3c). In
contrast, administration lansoprazole for 12 weeks induced an
osteomalacia-like condition such as decreased trabecular thickness
Fig. 7. Lansoprazole stably ﬁts in a pocket of CYLD and attenuates its deubiquitination activity in vitro. (a) Lansoprazole was incapable of enhancing TRAF6-anchored
autopolyubiquitination in vitro. (b) Lansoprazole suppressed the deubiquitination activity of CYLD. (c) Simulated crystal structure of CYLD (PDB id: 2VHF) bound to ubiquitin (blue)
(PDB id: 1NBF). The C-terminal tail of ubiquitin extends to the active site (yellow). Lansoprazole (green) ﬁts into a pocket to cross the C-terminal tail of ubiquitin. (d) Enlarged image
of a pocketwhere lansoprazole (sticks) ﬁts. Note that lansoprazole crosses the C-terminal tail of ubiquitin (blue). R758 (red) and F766 (purple) are artiﬁciallymutated to alanine to deform
the lansoprazole pocket. (e) Thewild-type CYLD retained the suppressive effects of lansoprazole on CYLD. (f) The R758A-single-mutant CYLDpartially abrogated the suppressive effects of
lansoprazole on CYLD. (g) The R758A and F766A-double-mutant CYLD completely abolished the suppressive effects of lansoprazole on CYLD.
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clastogenesis (Figs. 10b and S3d).
4. Discussion
Our drug repositioning study revealed that lansoprazole, a proton
pump inhibitor, has bone anabolic activity through upregulation of
Runx2 and serves as an enhancer of BMP signaling. Using the drug repo-
sitioning strategy, Mundy and colleagues identiﬁed that statins that are
commonly prescribed for hyperlipidemia enhance the BMP2 promoteractivity (Mundy et al., 1999). Similar to lansoprazole, statins stimulate
bone formation in animal models (Gutierrez et al., 2008). However,
statins may (Edwards et al., 2000) or may not (Esposito et al., 2013) in-
crease bonemineral density and prevent osteoporotic fractures in post-
menopausal women. BMP-2 is a potent osteoinductive agent that is
required for the initiation of fracture healing (Tsuji et al., 2006) and
for the development and maturation of osteoblasts (Chen et al.,
2012a). BMP-2, however, is also capable of inducing pluripotentmesen-
chymal cells into multiple lineages such as osteoblasts, chondrocytes,
and adipocytes (Date et al., 2004). Controversial effects on bone
Fig. 8. Proposed model of lansoprazole-induced activation of Runx2. Lansoprazole activates TRAF6-catalyzed Lys63-linked autopolyubiquitination of TRAF6 itself by inhibiting a speciﬁc
deubiquitination enzyme, CYLD. Lys63-linked polyubiquitinated chains of TRAF6, in turn, trigger autophosphorylation of TAK1. Unlike Lys48-linked polyubiquitination in protein degra-
dation, Lys63-linked polyubiquitination of TRAF6 activates TRAF6. The TAK1–p38 MAPK pathway, a noncanonical BMP pathway, then activates transcriptional activity of Runx2, which
requires recruitment of a transcriptional coactivator, CBP. The binding of BMP ligand to BMPRI and BMPRII markedly potentiates lansoprazole-induced activation of Runx2.
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On the contrary, Runx2 exclusively induces osteochondroblastogenesis
(Komori, 2010), but Runx2 alone is not sufﬁcient to induce the matura-
tion of osteoblasts (Lee et al., 2000). Runx2 is upregulated by BMPs
(Phimphilai et al., 2006), and the two molecules orchestrate to induce
the development and maturation of osteoblasts (Leboy, 2006). Upregu-
lation of BMPs by statins and upregulation of Runx2 by lansoprazole are
expected to coordinately accelerate osteoblastogenesis, but further
studies are required.
BMP ligands bind to BMPRII, and facilitates the formation of a
heterotetrameric receptor complex comprised of BMPRI and BMRPII,
which then activates the canonical pathway through phosphorylation
of the receptor-regulated Smads as well as the noncanonical MAPK
pathways (Katagiri and Tsukamoto, 2013). For Runx2 activation, both
canonical and noncanonical pathways play essential roles inmesenchy-
mal precursor cells (Lee et al., 2002). Among the noncanonical path-
ways, activation of the TAK1–p38 MAPK axis is essential for Runx2
activation in mesenchymal precursor cells (Greenblatt et al., 2010).
BMP-mediated formation of a BMPRI-II complex additionally induces
accumulation of TRAF6 on the complex. TRAF6 is a ubiquitin ligase as
well as a substrate polyubiquitinated by itself. The accumulation of
TRAF6 enhances the synthesis of Lys63-linked autopolyubiquitin chains.
The polyubiquitin chains confer a scaffold for the TAB-mediated adja-
cent placement of two TAK1molecules, which leads to autophosphory-
lation of TAK1 (Xia et al., 2009; Landstrom, 2010; Sorrentino et al.,
2008). The phosphorylated TAK1 then phosphorylates p38 MAPK. The
activated p38 MAPK also activates other transcriptional factors that
are essential for bone formation including Osterix and distal-less ho-
meobox 5 (Dlx5) (Ulsamer et al., 2008; Ortuno et al., 2010). Dissection
of underlying molecular mechanisms of the effect of lansoprazole re-
vealed that lansoprazole has little or no effects on the canonical path-
way, but activates the noncanonical TRAF6–TAK1–p38 MAPK pathway.
The tumor suppressor CYLD speciﬁcally digests Lys63-linked
polyubiquitin chains that are attached to the TNF receptor-associated fac-
tors, TRAF2 andTRAF6, aswell as an essential NF-κB signaling component,
NF-κB essential modulator (NEMO) (Brummelkamp et al., 2003;
Kovalenko et al., 2003; Trompouki et al., 2003). Among the CYLD-
catalyzed molecules, TRAF6 is the only molecule in the TGF-β–BMPpathway (Xie, 2013). In previous in vitro studies using puriﬁed proteins,
CYLD was able to cleave unanchored polyubiquitin chains, but not
polyubiquitin chains conjugated to TRAF6 (Xia et al., 2009). An
ubiquitin-conjugating E2 enzyme, UbcH5c, catalyzes both Lys63- and
Lys48-polyubiquitin chains either anchored or unanchored to TRAF6,
whereas another E2 enzyme, Ubc13, efﬁciently catalyzes unanchored
Lys63-polyubiquitin chains (Xia et al., 2009).We thus examined the effect
of lansoprazole on the deubiquitination activity of CYLD using unan-
chored polyubiquitin chains synthesized with UbcH5c (Fig. 7b) and
Ubc13 in vitro (Fig. 7e), and we only used Ubc13 for the subsequent mu-
tagenesis studies of CYLD (Fig. 7f and g). It is interesting to note that even
TRAF6-catalyzed unanchored polyubiquitin chains are capable of activat-
ing TAK1 (Xia et al., 2009). Thus, in addition to the induction and acceler-
ation of TRAF6-anchored polyubiquitin chains by lansoprazole (Fig. 6c
and d), stabilization of unanchored polyubiquitin chains by lansoprazole
(Fig. 7b and e) may partly account for the activation of TAK1.
TRAF6 is an essential factor for osteoclastogenesis as evidenced by
osteopetrotic phenotypes in TRAF6-deﬁcient mice (Lomaga et al.,
1999; Naito et al., 1999). TRAF6 is indispensable for signal transduction
downstream of RANK–RANKL pathway by binding to the cytoplasmic
tail of RANK (Inoue et al., 2000). Dissection of TRAF6 domains demon-
strated that different domains of TRAF6 regulate osteoclast differentia-
tion, maturation, and function (Kobayashi et al., 2001). The RING
ﬁnger domain of TRAF6, which is critical for the ubiquitin E3 ligase ac-
tivity, is not crucial for osteoclast differentiation but is essential for full
maturation and activation of osteoclasts. Likewise, CYLD-deﬁcient
mice, in which more polyubiquitinated TRAF6 was accumulated, had
enlarged osteoclasts (Jin et al., 2008). In addition, bone marrow cells
from the CYLD-deﬁcientmice exhibited enhanced expressions of osteo-
clastic marker genes upon RANKL stimulation. Therefore, lansoprazole-
mediated increased osteoclast maturation and bone resorbing activity
in cellulo, which were also demonstrated at the intact metaphyses of
the unfractured femurs in vivo, provide supportive evidence that CYLD
and TRAF6 are the molecular targets of lansoprazole. In contrast, in a
rat model of femoral fracture, lansoprazole promotes osteoblastic mat-
uration and impairs osteoclastogenesis both at the fracture site and
the injured metaphyses, where BMP is induced for bone regeneration.
Although the mechanisms underlying the different effects of
Fig. 9. Lansoprazole activates osteoclast formation and bone resorption activity. (a) Effects of lansoprazole on osteoclast formation and maturation. RAW264.7 cells were cultured for 4 d
with orwithout lansoprazole in the presence of 100 ngmL−1 RANKL. TRAP-positive cellswithmore than 3 nuclei were counted as osteoclasts. The numbers of total andmature osteoclasts
are shown on the top. Representative TRAP-stained cell images are shown at the bottom. †p b 0.0000001, *p b 0.0005, **p b 0.04, and ***p b 0.0001 by one-way ANOVA with post-hoc
Dunnett analysis. Scale bar, 1 mm. (b) Effects of lansoprazole on osteoclast function. RAW 264.7 were cultured on a calcium phosphate-coated plate with or without lansoprazole in
the presence of 100 ng mL−1 RANKL for 7 d. Sizes of the eroded areas are shown on the top. Representative images of the resorption pits are shown at the bottom. Scale bar, 2 mm.
*p b 0.04, **p b 0.03, and ***p b 0.02 by one-way ANOVA with post-hoc Dunnett analysis.
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bones remain unknown, suppression of osteoclastogenesis at the frac-
ture site by lansoprazole is predicted to be favorable for facture healing.
The FDA announced a safety alert regarding the possible association
between the risk of fractures and the use of PPIs in aged individuals(Ngamruengphong et al., 2011), although the exactmechanisms remain
controversial. The adverse effectmay be attributed to decreased absorp-
tion of insoluble calciumdue to the elevated gastric pH observed in aged
women taking PPIs (O'Connell et al., 2005). Alongwith this observation,
mice deﬁcient for Cckbr encoding a gastrin receptor that facilitates
Fig. 10. Systemic administration of lansoprazole enhances osteoclastogenesis and induces osteomalacia-like change at the metaphyses of unfractured rat femurs. (a) Histomorphometric
analyses of undecalciﬁed histology in rats that were administered with lansoprazole for 4 weeks. The mean ± SD (n= 4) are indicated. *p b 0.05 (ES/BS) and *p b 0.03 (Oc.S/BS) by un-
paired t-test. Lanso., lansoprazole; and NS, not signiﬁcant. (b) Histomorphometric analyses of undecalciﬁed histology in rats that were administered with lansoprazole for 12 weeks. The
mean ± SD (n= 4) are indicated. *p b 0.02 (Tb.Th) and *p b 0.04 (O.Th) by unpaired t-test. Lanso., lansoprazole; and NS, not signiﬁcant.
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and mice deﬁcient for gastric H+–K+ ATPase beta-subunit also show
decreased bonemineral density (Fossmark et al., 2012). A retrospective
study, however, shows that patients taking high doses of PPIs do not
have low bone mineral density or increased rate of bone loss
(Targownik et al., 2010). We demonstrated that lansoprazole could in-
duce osteopenia and fragility at the metaphyses of unfractured long
bones by alteration of the trabecular structures to an osteomalacia-like
condition and increased bone resorption of the trabeculae. Previously,
the maturational blockage of osteoblasts and osteopenia have been re-
ported in mice overexpressing Runx2 (Liu et al., 2001). PPIs-mediated
increased chance of fragility fractures is thus likely to be attributed to
sustained activation of Runx2 and partly to enhancement of osteoclast
maturation.
Lansoprazole and other PPIs have been widely used for more than
20 years in the prevention and treatment of the acid-related disorders
such as gastroduodenal ulcers and reﬂux esophagitis, although the mo-
lecular bases of the proton pump-inhibiting effects of lansoprazole re-
mains elusive. In spite of their efﬁcacy, long-term use or high dose of
PPIs have been implicated to provoke several adverse effects including
increased pneumonia, Clostridium difﬁcile-associated disease, fragility-related fractures, neoplasms, iron deﬁciency, and acute interstitial ne-
phritis (Moayyedi and Leontiadis, 2012; Chen et al., 2012b). As chronic
activation of TGF-β–BMP signal transmission causes detrimental
cellular processes including ﬁbrosis, atherosclerosis, tumorigenesis,
cancer metastasis, and autoimmune disorders (Akhurst and Hata,
2012), enhancement of the TGF-β–BMP signaling by lansoprazole may
partly account for some of these adverse effects. A recent report showed
that osteogenic induction of human MSCs in the presence of
lansoprazole (10–1000 μM) for a longer period (N14 d) decreased ALP
activity (Costa-Rodrigues et al., 2013). In addition, higher concentra-
tions (100–1000 μM) of lansoprazole for 7 d or more attenuated cell
proliferation by inducing apoptosis. In contrast, we conﬁrmed increased
ALP activity in human bone marrow-derived mesenchymal cells that
were treated with 5–40 μM lansoprazole for up to 6 d (Fig. 1e and f).
Therefore, even in fresh bone marrow cells, longer exposure of
lansoprazole may inhibit ALP activity at lower concentrations. An off-
label higher dose of lansoprazole in the context of osteogenesis promo-
tion is thus expected to be limited to either short-term or local usage.
We have started developing a biodegradable artiﬁcial bone that en-
ables a sustained release of concentrated lansoprazole. We believe that
the combined use of lansoprazole with biomaterials would lead to the
2060 K. Mishima et al. / EBioMedicine 2 (2015) 2046–2061invention of a unique bone graft substitute that possesses the capacity
of osteoinduction in addition to osteoconduction. In addition,
lansoprazole alongwith the osteogenicmediummaybe able to enhance
osteoblastic differentiation of bonemarrow derivedmesenchymal stro-
mal cells ex vivo. Although detailed absorption, distribution, metabo-
lism, excretion, and toxicity (ADMET) analysis is required for ex vivo
application of lansoprazole, the probability of unpredicted adverse ef-
fects is expected to be lower than chemical compounds that have
never been used in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.11.024.
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